Rentosertib phase 2a results are published in Nature Medicine
In June 2025 Nature Medicine published a phase 2a trial of rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis that was discovered by an AI platform, together with early signs of a lung-function effect.